Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phases I/II of FLD-103, an intralesional treatment against basal cell carcinoma (BCC)

Next Previous
Trial Profile

A phases I/II of FLD-103, an intralesional treatment against basal cell carcinoma (BCC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FLD 103 (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Feldan Therapeutics

Most Recent Events

  • 31 Oct 2024 Status changed from planning to recruiting, according to a Feldan therapeutic media release.
  • 31 Oct 2024 According to a Feldan therapeutic media release, company announced its first patient being dosed in Phase 1/2a clinical study of Lead development candidate FLD-103; an intralesional injection intended to provide an alternative to surgery to patients diagnosed with basal cell carcinoma (BCC).
  • 04 Sep 2024 According to a Feldan therapeutic media release, the company received a US$ 21 million Series B round co-led by Genesys Capital (Genesys) and Fonds de solidarite FTQ (Fonds) proceeds from this trial will be used to complete this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top